Alopecia areata
☆ A cikin sakamakon Stiftung Warentest na 2022 daga Jamus, gamsuwar mabukaci tare da ModelDerm ya ɗan yi ƙasa kaɗan fiye da biyan shawarwarin telemedicine.
Ana ganin Alopecia areata a bayan fatar kai. A cikin al'amuran al'ada, yana bayyana ba zato ba tsammani tare da shimfidar wuri mai santsi kuma girman 2-3 cm.
References
Alopecia areata shine yanayin da garkuwar garkuwar jikinka ke kai hari ga lungu da sako na gashin kai, wanda hakan ke janyo asarar gashi na dan lokaci ba tare da tabo ba. Zai iya nunawa a matsayin facin asarar gashi ko kuma ya shafi dukkan gashin kai ko jikinka, yana tasiri kusan kashi 2% na mutane a wani mataki na rayuwarsu. Babban mai laifi yana da alama ya zama raguwa a cikin kariyar halitta a kusa da gashin gashi.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Alopecia areata affects nearly 2% of the general population at some point during their lifetime. A breakdown of immune privilege of the hair follicle is thought to be an important driver of alopecia areata.
Alopecia areata wani yanayi ne da garkuwar jiki ke kai hari kan gabobin gashi, yana haifar da zubewar gashi a kai da sauran sassan jiki. Yana shafar kusan kashi 2% na mutane a duniya. Duk da yake yana iya faruwa a kowane zamani, yana da yawa a cikin yara fiye da manya (1. 92% vs. 1. 47%) . Mata, musamman ma wadanda suka haura 50, sun fi samun kwarewa fiye da maza. Curar corticosteroids kai tsaye zuwa wuraren da abin ya shafa ya nuna sakamako mai kyau fiye da amfani da su a kai.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
Alopecia areata is an immune-mediated condition leading to non-scarring alopecia of the scalp and other hair-bearing areas of the body. It affects up to 2% of the global population. It can affect all ages, but the prevalence appears higher in children compared to adults (1.92%, 1.47%). A greater incidence has been reported in females than males, especially in patients with late-onset disease, defined as age greater than 50 years. Intralesional injection of corticosteroids has been reported to lead to better responses compared to topical steroids.
An yi imani da alopecia areata cuta ce ta autoimmune da ke da alaƙa da tsarin rigakafi na follicles gashi. Tsarin tushen ya ƙunshi gazawar jiki don gane sel nasa, tare da lalacewa ta hanyar rigakafi na gaba ga ƙwayar gashi.
○ maganin - Magungunan OTC
Wasu mutanen da ke da alopecia areata suna warkewa cikin shekara guda ba tare da magani ba. Koyaya, yawancin mutane suna fuskantar sake dawowa a wuraren da bazuwar a kan fatar kai.
#Hydrocortisone cream
○ maganin
Intralesional steroid injections ne mafi tasiri magani. Ana iya gwada maganin rigakafi idan an shafi manyan wuraren fatar kan mutum.
#Triamcinolone intralesional injection
#DPCP immunotherapy